Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

The Trump administration wants to bring the production of more drugs, including medicines like antibiotics that may be in ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

U.S. equities were mixed at midday, with the Dow Jones Industrial Average and S&P 500 slightly higher and the Nasdaq ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Hospital nurses immediately diagnosed Kelly with type 1 diabetes, a non-communicable disease (NCD), and put her on a treatment regimen that she will likely need to follow for the rest of her life.

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...